American Association for Cancer Research: AZD1390 With Radiotherapy Shows Manageable Safety Profile and Preliminary Efficacy for Patients With Glioblastoma in Phase I Trial
April 10, 2024
April 10, 2024
SAN DIEGO, California, April 10 (TNSres) -- The American Association for Cancer Research issued the following news release:
AZD1390, an ataxia telangiectasia mutant (ATM) kinase inhibitor, demonstrated a manageable safety profile in both recurrent and newly diagnosed glioblastoma (GBM) patients when given in combination with standard-of-care radiotherapy and showed preliminary efficacy in recurrent GBM patients, according to results from a global phase I trial presented at the Ameri . . .
AZD1390, an ataxia telangiectasia mutant (ATM) kinase inhibitor, demonstrated a manageable safety profile in both recurrent and newly diagnosed glioblastoma (GBM) patients when given in combination with standard-of-care radiotherapy and showed preliminary efficacy in recurrent GBM patients, according to results from a global phase I trial presented at the Ameri . . .